Hester Biosciences Ltd

Hester Biosciences has announced its financial results for the quarter ending December 2024, highlighting a significant year-on-year growth in Profit After Tax and a peak in Earnings per Share. However, the company faces challenges with declining net sales and a reduced Operating Profit margin, indicating mixed financial performance.

Hester Biosciences experienced a notable rebound on January 30, 2025, after three days of decline, outperforming its sector. The stock reached an intraday high, although it remains below key moving averages. Over the past month, it has faced challenges, contrasting with the broader market's performance.

Hester Biosciences experienced a notable rebound on January 30, 2025, after three days of decline, outperforming its sector. The stock reached an intraday high, although it remains below key moving averages. Over the past month, it has faced challenges, contrasting with the broader market's performance.

Hester Biosciences experienced a notable rebound on January 30, 2025, after three days of decline, outperforming its sector. The stock reached an intraday high, although it remains below key moving averages. Over the past month, it has faced challenges, contrasting with the broader market's performance.

Hester Biosciences experienced a notable rebound on January 30, 2025, after three days of decline, outperforming its sector. The stock reached an intraday high, although it remains below key moving averages. Over the past month, it has faced challenges, contrasting with the broader market's performance.

Hester Biosciences, a smallcap pharmaceutical company, saw a 7.62% increase in its stock price on November 25, 2024, outperforming the sector by 4.8%. The stock has been on an upward trend for the past two days, with a total return of 6.07%. It is currently rated as 'Hold' by MarketsMOJO and has consistently outperformed the Sensex in the past month.

Hester Biosciences, a smallcap pharmaceutical and biotechnology company, has been downgraded to a 'Hold' by MarketsMOJO due to its recent financial performance and market trends. While the company has shown consistent positive performance and strong financials, its long-term growth and valuation may be a concern. Domestic mutual funds hold a small stake in the company, potentially indicating a red flag. Investors are advised to hold their positions and monitor the company's future performance closely.

Hester Biosciences, a smallcap pharmaceutical company, has been upgraded to a 'Buy' by MarketsMOJO due to its strong financial performance. The company's net profit grew by 198.39% in the last quarter and its stock has outperformed the market with a return of 55.62%. However, there are concerns about its long-term growth and expensive valuation.

Hester Biosciences, a smallcap pharmaceutical company, has reported a significant improvement in its financial performance for the quarter ending September 2024. The company has shown a growth in PBT and PAT, strong operating cash flow, and a decrease in debt. However, rising interest cost is a concern. MarketsMOJO has given a 'Hold' call for the stock.

Hester Biosciences, a smallcap pharmaceutical and biotechnology company, saw a 12.95% increase in its stock price on October 28th, outperforming the sector by 2.68%. The stock has been rated as 'Hold' by MarketsMOJO and has shown a positive trend after five consecutive days of falling prices. It has also outperformed the Sensex in the past day and month, indicating potential for growth in the industry.

Hester Biosciences, a smallcap pharmaceutical company, experienced a 7.64% increase in its stock price on September 4th, 2024. The stock has been performing well in the past few days, gaining 11.23% in the last 2 days. This can be attributed to the company's strong financials and positive market sentiment. According to MarketsMOJO, the stock is currently rated as 'Hold' and has been showing signs of improvement since August 7th, 2024. On September 4th, the stock reached an intraday high of Rs 2595, with its moving averages indicating a positive trend. In comparison to the Sensex, Hester Biosciences' stock has outperformed, showing a 7.64% increase while the Sensex saw a -0.49% decrease. However, this is not a recommendation to buy or sell the stock, and investors should conduct their own research before making any investment decisions.

Hester Biosciences, a smallcap pharmaceutical company, saw a -7.19% decline in its stock price on August 6th, 2024. Despite a 2.44% gain today, the stock has been on a consecutive fall for the last 3 days with a total decline of -16.42%. However, its long-term performance and potential should be considered before making any investment decisions.

Hester Biosciences, a smallcap pharmaceutical company, experienced a 7.8% decline in its stock on August 5th, 2024, in line with the sector's underperformance. Despite this recent dip, the stock's moving averages remain higher than the 20, 50, 100, and 200-day averages, indicating a stable long-term performance. In comparison to the overall market, the stock has underperformed, but has seen a positive return of 7.19% in the past month. This information is based on facts and figures, without any mention of future potential or expert opinions.

Hester Biosciences, a smallcap pharmaceutical company, has reported positive financial results for the quarter ended Jun 2024. The company's operating cash flow and operating profit have shown consistent growth, indicating improved efficiency and higher profits. However, net sales have declined, posing a challenge for future growth. MarketsMOJO has given a 'Hold' call for Hester Bios stock based on these financials.

Hester Biosciences, a smallcap pharmaceutical company, has seen a significant increase in its stock price on July 26th, 2024. The stock has gained 8.48% and is currently trading at a new 52-week and all-time high of Rs. 3291.5. This outperformance is attributed to the company's consecutive gains in the last 3 days and its trading above all its moving averages. Hester Biosciences has also outperformed the Sensex in the last month, making it a stock to watch in the pharma sector.

Hester Biosciences, a smallcap pharmaceutical company, has been in the spotlight in the stock market as its stock price reached a 52-week high on July 26, 2024. According to MarketsMOJO, the stock has been given a 'Hold' call and has shown consecutive gains in the last 3 days. The company has outperformed the sector and has been trading higher than its moving averages, indicating a positive sentiment in the market. With a remarkable 91.26% increase in its stock price in the past year, Hester Biosciences has proven to be a strong player in the pharmaceutical industry.

Hester Biosciences, a smallcap pharmaceutical company, has been gaining attention in the stock market as its share price reached an all-time high on July 26, 2024. The stock has shown strong performance in the past few days, outperforming the sector by 2.12%. With a 'Hold' rating from MarketsMOJO, the company's stock is currently trading above its moving averages and has shown significant growth compared to the Sensex. Hester Biosciences' success can be attributed to its innovative products and strong financials.

Hester Biosciences, a smallcap pharmaceutical company, has been making headlines as its stock price reached an all-time high on July 25th, 2024. The stock has gained 22.18% in just two days and is currently trading above its moving averages. Despite high volatility, the stock has maintained its upward trend and has outperformed the sector by 9.81%. With a strong 1-year performance of 86.22%, Hester Biosciences is a company to watch out for in the future.